Navigation Links
CEL-SCI's Cel-1000 Shown to Significantly Enhance Immune Response,Against Hepatitis B Antigen in Animals

VIENNA, Va., May 01, 2007 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION announces that CEL-1000 alone increased the immune response against hepatitis B antigen, and that the combination of CEL-1000 with MAS-1, a proprietary water-in-oil adjuvant delivery system owned by Mercia Pharma, induced highly significant increases in specific anti-HBV (hepatitis B virus) antibodies. These findings were presented by Dr. Daniel Zimmerman, Senior Vice President of Research, Cellular Immunology at CEL-SCI at the 10th Annual Conference of the National Foundation for Infectious Diseases in Baltimore, Maryland.

This new finding with CEL-1000 may have broad application for the enhancement of immune responses by individuals who have a poor immune response to vaccinations. It also has application for antigen sparing (reducing the amount/dose of antigen) required for protective immunity, and application to biodefense and pandemic settings for anti-infectious vaccines.

Dr. Zimmerman said, "A good number of people, a great majority of them middle aged and older men, vaccinated against Hepatitis B fail to generate high enough levels of antibodies to be considered protected. These individuals need and deserve a better level of protection."

CEL-1000 has previously been shown to be protective in animal challenge studies against viruses and unrelated diseases, specifically herpes simplex virus, viral encephalitis and malaria. CEL-1000 appears to activate innate (very early stage) and Th1 type (cellular) immune responses to induce a broad- spectrum protection against infection in animal models. The innate immune system is generally accepted to be the first line of defense against infectious agents.

CEL-1000, derived from the beta chain of human MHC-II, is a modified version of a human immune-based protein known to bind to both human and mouse immune cells and appears to act by enhancing the host's protective imm
'"/>




Page: 1 2

Related medicine technology :

1. RTA 402 Shown to Protect Animals Against Toxicities of Standard Cancer Treatments
2. Gabapentin Shown Effective for Fibromyalgia Pain
3. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
4. CEL-SCIS CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals
5. Efficacy and Safety Profile of Basileas Alitretinoin for Severe Refractory Chronic Hand Eczema Confirmed by Data Shown at European Dermatology Congress
6. Innovative Cancer Drug MabThera Again Shown To Improve Survival Rates In Patients With Lymphoma
7. RTA 402 Shown to Inhibit STAT3 in Animal Model and Holds Significant Promise for Treating Breast Cancer
8. Accelreon Pharmas ACE-031Shown to Increase Muscle Mass in Preclinical Studies
9. Cethromycin Shown Effective Against Anthrax in Study
10. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
11. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension

Post Your Comments:
(Date:11/25/2009)..., SANDIEGO,Nov.25/PRNewswire-FirstCall/--NuVasi...dondevelopingproductsforminimallydisruptivesurgica...taconferencecallonMonday,November30,2009,at5:30p.m...issuesrelativetoreimbursementfortheCompany,sproduc...hortquestionandanswersession.Thedial-innumbersare1...
(Date:11/25/2009)..., NEWYORK,Nov.25/PRNewswire/--Reportlinker.coma...tscatalogue: ,, IntranasalDrugDelivery-USMarke...p0164267/Intranasal-Drug-Delivery---US-Market-Tren...rymarketiswitnessinganexpansionoftherapeuticapplic...cdrugstothedeliveryofsystemictherapeuticdrugs.Thef...
(Date:11/25/2009)..., MOUNTAINVIEW,Calif.,Nov.25/PRNewswire/-- Che...aldatafromtheCompany,sPROTECT-1(theProspectiveRand...fTraficet-EN(TM)(CCX282-B)inpatientswithmoderate-t...withafavorablesafetyandtolerabilityprofile.Thestud...ionofdiseaseseverityasdefinedasa70-pointdecreasein...
Breaking Medicine Technology:NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5OxySure 28R 29 Aids Student in School Respiratory Arrest 3A WFAA Channel 8 News 5835 1OxySure 28R 29 Aids Student in School Respiratory Arrest 3A WFAA Channel 8 News 5835 2OxySure 28R 29 Aids Student in School Respiratory Arrest 3A WFAA Channel 8 News 5835 3Burton Medicals New Diagnostic Examination Light the AIM LED Provides 10 Percent More Illumination and 10 Times Greater Lamp Life 5833 1Burton Medicals New Diagnostic Examination Light the AIM LED Provides 10 Percent More Illumination and 10 Times Greater Lamp Life 5833 2Rogan Delft Approves Matrox Xenia Series for Use With Zillion Suite 5831 1Rogan Delft Approves Matrox Xenia Series for Use With Zillion Suite 5831 2Rogan Delft Approves Matrox Xenia Series for Use With Zillion Suite 5831 3
...SynergEyes, Inc., the high Dk hybrid contact lens ... million in Series C financing to fund the develop...d contact lens products and to expand sales and ma...f Palo Alto, CA, led this round as well as SynergE...joined Series A and B investors: Alloy Ventures, D...
...e of Cardiology publishes positive ATLAS clinical ... Corporation (NYSE: BSX ) today announced that i...ration (FDA) the final modules of the Company,s Pr...TAXUS(R) Liberte(R) Atom(TM) Paclitaxel-Eluting Co... Paclitaxel-Eluting Coronary Stent System. If app...
Other Medicine Technology:SynergEyes, Inc. Raises $13.3 Million in 'Series C' Financing 2Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents 2Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents 3Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents 4Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents 5
(Date:11/25/2009)...ire/--WhenmostpeopleheartheacronymTMJ,theythinkoft...helptheyneed.TMJstandsfortheTemporal-MandibularJoi...ithyourskull(temporalbone). ,, Themostcommonsym...g,clickingorpoppingofthejaw.Butmanyothersymptomsca...igue,sleepdisturbances,irritability,alossinfocus,r...
(Date:11/25/2009)...MedicalInc.,aleadingmanufacturerofbreastMRIcoilsan...eadingedgeclinicalapplicationsonitsAegis(TM)medica...cietyofNorthAmerica(RSNA)annualmeetinginChicago,No...veragetheuniquehighqualityimagesgeneratedbySentine...magingmodalitiesformulti-parametricassessment. ,...
(Date:11/25/2009)...ayAreaAirQualityManagementDistrictisissuingtheseas... forThursday,November26,2009whichbansburningwood,m...andoutdoors. ,, "Cold,stillweatherwillcontribut...executiveofficeroftheAirDistrict."We,reaskingBayAr...llowcommunitymembersthisThanksgiving,andnottoburnw...
(Date:11/25/2009)... collaboration between UCLA engineers and physicia...illion Americans who suffer from peripheral arteri... arteries, peripheral arterial disease, or PAD, is...teries reduce blood flow to the limbs. The conditi...heart attack and stroke, and its progression can r...
(Date:11/25/2009)...tment clinics to resume Monday, Nov. 30 , ...09 -- Centegra Health System is continuing to offe...ur Centegra Primary Care (CPC) vaccination clinics...e clinics are at CPC sites in Huntley, Woodstock, ...ws: ,   From 4:30 to 7:30 p.m. Tuesday...
Breaking Medicine News(10 mins):Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 3Health News:Winter Spare the Air Alert in Effect for Thursday, November 26, 2009 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4
...ts , , FRIDAY, Nov. 21 (HealthDay News) -...at child,s risk of asthma, new research suggests. ...e the peak of winter virus season -- have almost a...Journal of Respiratory and Critical Care Medicine ...
... are not given adequate drug therapy. This is the ...dition of Deutsches rzteblatt International ( Dt...r et al. present the German results of this prospe...cardiovascular diseases and 10.8% only exhibited r...
...oration (NYSE: HUN ) today announced that its Fo...r Americans chosen by the American Cancer Society ... honor. Given annually, the,award is reserved for...or,personally contributed over $600 million to the...
...utual Life,Insurance Company (MassMutual) today an...ng Officers. , -- Roger W. Crandall, Co-Chie...Chief Investment Officer, will assume the position...Operating Officer,and join the company,s Board of ...
...Inc.,( http://www.cardiosolutionsinc.com ) has ann... Ph.D. to the position of Chief Surgical Officer. ...er for Aortic Surgery and Director of the,Marfan S...c. is developing its proprietary Percu-Pro(TM) Sys...
...ocated in,Pittsburgh PA, and a subsidiary of Draeg...ountering what it believes are unsubstantiated all...formerly Bacou-Dalloz USA) of a patent,infringemen... property rights, but,believes that this lawsuit i...
Other Medicine News:Health News:Autumn Babies More Prone to Asthma 2Health News:Autumn Babies More Prone to Asthma 3Health News:Jon M. Huntsman Receives American Cancer Society Medal of Honor 2Health News:MassMutual Announces Promotions for Two Co-Chief Operating Officers 2Health News:MassMutual Announces Promotions for Two Co-Chief Operating Officers 3Health News:MassMutual Announces Promotions for Two Co-Chief Operating Officers 4Health News:MassMutual Announces Promotions for Two Co-Chief Operating Officers 5Health News:Cardiosolutions Names Dr. Lars Svensson Chief Surgical Officer 2Health News:Draeger Counters What It Believes Are Unsubstantiated Allegations of Patent Infringement by Sperian 2
Basic modular VICTOR2 Multilabel Counter (3 technologies)
VICTOR2 V (5 technologies), manual model
VICTOR2 multilabel counter with stacker and robot loading
... 96-channel parallel detection of fluorescence, ab...l microtiter plates. Compact workstations and sys...ansport of microtiter plates with a throughput of ... switching required by numerous other systems to s...
Medicine Products: